BTG plc (LSE: BGC), the specialty pharmaceuticals company, today announces that it has licensed exclusive worldwide rights to Allergan to develop products for diseases and conditions of the eye using BTG’s ReGel® drug delivery system. Under the terms of the agreement, BTG will receive an undisclosed upfront payment, and potential additional future milestones and royalties on product sales.
